J.P. Morgan Resumes Coverage of Endo Pharmaceuticals with Overweight and PT of $50

J.P. Morgan resumed coverage of Endo Pharmaceuticals ENDP with an Overweight rating and a price target of $50. In a research report published today, J.P. Morgan states, "Due to the completion of J.P. Morgan's involvement in the transaction announced on April 11, 2011, we are resuming coverage of Endo Pharmaceuticals (ENDP) with an Overweight rating (previously Overweight) and a December 2011 price target of $50 (previously $45)." On Monday, Endo ended the day at $38.37.